Dr. Vlad Vitoc about the MAIA IPO at Rejuvenation Startup Summit 2022
We are happy to announce Dr. Vlad Vitoc, MD, MBA, CEO and President of MAIA Biotechnology, Inc. as a speaker for the Rejuvenation Startup Summit 2022.
Vlad will talk about MAIAs recent IPO at NYSE and the company’s second-generation telomere targeting agents.
Dr. Vlad Vitoc, MD, MBA is Chairman of Board, CEO and President of MAIA Biotechnologies. Dr. Vitoc has a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. During that time, Dr. Vitoc has managed and supported over 20 early, launch, and mature stage compounds, which have included targeted therapies and immune therapies across more than 25 tumor types, including colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, and renal cell carcinoma. Vlad received an M.D. from the University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina.
About the Rejuvenation Startup Summit 2022
The Rejuvenation Startup Summit (Berlin, Oct. 14-15, 2022) hosted by the Forever Healthy Foundation, is a vibrant networking event that aims to accelerate the development of the rejuvenation biotech industry.
Rejuvenation/Longevity biotech is a new, emerging field of medicine. It aims to prevent and reverse diseases of aging by addressing their common root cause, the aging process itself. Rejuvenation therapies aim to reverse or repair age-related cellular changes such as molecular waste, calcification, tissue stiffening, loss of stem cell function, genetic alterations, and impaired energy production.
The Rejuvenation Summit brings together startups, members of the longevity venture capital / investor ecosystem, and researchers interested in founding or joining a startup – all aiming to create therapies to vastly extend the healthy human lifespan.
Further information can be found at www.forever-healthy.org/summit/
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
For more information, please visit www.maiabiotech.com.